PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1545136-5 1992 GM-CSF bioactivity increased in cell supernatants from keratinocytes exposed in vitro to 1 microgram/ml cyclosporin for up to 24 h. GM-CSF and IL-1 mRNA levels in keratinocytes cultured under similar conditions or in the presence of lipopolysaccharide also increased. Cyclosporine 104-115 interleukin 1 complex Mus musculus 143-147 10382954-6 1999 Additional studies have shown that HC and CsA blocked con A-driven differentiation of CD8+ and CD4+ CD8+ lymph node cells (LNC) and progression of LNC to S + G2/M cell cycle phases, and inhibited IL-1, IL-2 and TGF-beta while enhancing GM-CSF gene expression in BM cells. Cyclosporine 42-45 interleukin 1 complex Mus musculus 196-200 1521932-3 1992 Besides confirming the finding that exogenous IL-1 leads to a rapid increase in CSF detection, we obtained evidence that IL-1 may also result in the production of cyclo-oxygenase pathway products that down-regulate the IL-1-induced burst in CSA and CSF-1 levels. Cyclosporine 241-244 interleukin 1 complex Mus musculus 46-50 1521932-3 1992 Besides confirming the finding that exogenous IL-1 leads to a rapid increase in CSF detection, we obtained evidence that IL-1 may also result in the production of cyclo-oxygenase pathway products that down-regulate the IL-1-induced burst in CSA and CSF-1 levels. Cyclosporine 241-244 interleukin 1 complex Mus musculus 121-125 1521932-3 1992 Besides confirming the finding that exogenous IL-1 leads to a rapid increase in CSF detection, we obtained evidence that IL-1 may also result in the production of cyclo-oxygenase pathway products that down-regulate the IL-1-induced burst in CSA and CSF-1 levels. Cyclosporine 241-244 interleukin 1 complex Mus musculus 121-125 3873733-7 1985 The possibility that CsA actually affects interleukin-1 (IL-1) production by macrophages by inhibiting uninvolved T cells could be ruled out. Cyclosporine 21-24 interleukin 1 complex Mus musculus 42-55 2958556-13 1987 These data suggest that, in respect to this particular T cell line, IL-1 is directly growth-promoting or, alternatively, induces the production of undetectable, intermediate growth factor(s) resistant to inhibition by cyclosporine A. Cyclosporine 218-232 interleukin 1 complex Mus musculus 68-72 1728297-5 1992 Treatment of challenged mice with cyclosporin A (CyA) led to an abrogation of the disease as seen by an abrogation of the increase in lung index, lack of IL-1 and TNF-alpha release in the BAL. Cyclosporine 34-47 interleukin 1 complex Mus musculus 154-158 1761361-3 1991 In nongranulocytopenic mice, the combined treatment with IL-1 and bacterial cells also resulted in a biphasic pattern of CSA response. Cyclosporine 121-124 interleukin 1 complex Mus musculus 57-61 1761361-4 1991 However, when IL-1 was administered in concurrence with the cyclo-oxygenase inhibitor indomethacin, sustained CSA levels could be observed for a prolonged period of time. Cyclosporine 110-113 interleukin 1 complex Mus musculus 14-18 1761361-5 1991 These data expand upon our previous observations on modulation of CSA by IL-1 in granulocytopenic mice, and further support the concept that IL-1 may have both positive and negative effects on the expression of circulating CSA. Cyclosporine 66-69 interleukin 1 complex Mus musculus 73-77 2111738-7 1990 Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1. Cyclosporine 44-47 interleukin 1 complex Mus musculus 193-197 2111738-7 1990 Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1. Cyclosporine 149-152 interleukin 1 complex Mus musculus 193-197 2111738-7 1990 Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1. Cyclosporine 149-152 interleukin 1 complex Mus musculus 193-197 2111738-7 1990 Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1. Cyclosporine 149-152 interleukin 1 complex Mus musculus 193-197 2525802-8 1989 Both strains were, however, able to recover from the infection without functional T-helper lympho-cytes and/or the IL-1 IL-2 which had been inhibited by treatment with CsA. Cyclosporine 168-171 interleukin 1 complex Mus musculus 115-124 2671565-3 1989 Serum from IL-1 injected mice showed marked granulocyte/macrophage CSA (GM-CSA), but little megakaryocyte CSA (Meg-CSA). Cyclosporine 67-70 interleukin 1 complex Mus musculus 11-15 2671565-3 1989 Serum from IL-1 injected mice showed marked granulocyte/macrophage CSA (GM-CSA), but little megakaryocyte CSA (Meg-CSA). Cyclosporine 75-78 interleukin 1 complex Mus musculus 11-15 3497063-6 1987 Also, the actual ratio between neutrophilic and monocyte/macrophage colonies was reduced when compared to cultures stimulated in the presence of CSA, indicating that IL-1 increased myeloid differentiation. Cyclosporine 145-148 interleukin 1 complex Mus musculus 166-170 3497063-8 1987 Cultures with anti-CSA demonstrated a reduced number of CFU-GM when plated in the presence of CSA but not with IL-1, demonstrating the specificity of IL-1 to stimulate CFU-GM in the presence of anti-CSA antibody. Cyclosporine 19-22 interleukin 1 complex Mus musculus 150-154 3497063-8 1987 Cultures with anti-CSA demonstrated a reduced number of CFU-GM when plated in the presence of CSA but not with IL-1, demonstrating the specificity of IL-1 to stimulate CFU-GM in the presence of anti-CSA antibody. Cyclosporine 94-97 interleukin 1 complex Mus musculus 150-154 3497063-8 1987 Cultures with anti-CSA demonstrated a reduced number of CFU-GM when plated in the presence of CSA but not with IL-1, demonstrating the specificity of IL-1 to stimulate CFU-GM in the presence of anti-CSA antibody. Cyclosporine 94-97 interleukin 1 complex Mus musculus 150-154 3873733-7 1985 The possibility that CsA actually affects interleukin-1 (IL-1) production by macrophages by inhibiting uninvolved T cells could be ruled out. Cyclosporine 21-24 interleukin 1 complex Mus musculus 57-61 30664361-13 2019 CONCLUSIONS: This study indicates that the three CsA formulations effectively modulated TLR4, TGFbeta1, IL1, and IL6 pathways to reduce corneal epithelium lesions in a mouse model of severe dry eye. Cyclosporine 49-52 interleukin 1 complex Mus musculus 104-107 3876299-4 1985 The resistance to CsA of the mitogenic activity of IL-1 was unexpected since this response is assumed to be mediated by newly formed IL-2 and CsA inhibits IL-2 production. Cyclosporine 18-21 interleukin 1 complex Mus musculus 51-55 3876299-4 1985 The resistance to CsA of the mitogenic activity of IL-1 was unexpected since this response is assumed to be mediated by newly formed IL-2 and CsA inhibits IL-2 production. Cyclosporine 142-145 interleukin 1 complex Mus musculus 51-55 3876299-10 1985 Yet, this partial protection by IL-1 was achieved only at CsA concentrations about 100 fold lower than those resisted by thymocytes directly stimulated by IL-1. Cyclosporine 58-61 interleukin 1 complex Mus musculus 32-36